Argenx to acquire Forte Biosciences for $2.2 billion to expand immunology pipeline

Argenx has entered a definitive agreement to acquire Forte Biosciences for $2.2 billion, or $77 per share, representing an 86% premium. The acquisition centers on the lead asset FB102, an antibody currently in development for vitiligo, celiac disease, and alopecia, marking a significant expansion of Argenx's autoimmune therapeutic portfolio.